Big Pharma’s Patent Abuses Are Fueling the Drug Pricing Crisis
The latest in news from I-MAK experts.
For press inquiries, please contact simon@i-mak.org.
Tahir Amin: Pay-for-Delay Settlements and Patient Access
Tahir Amin: The Role of Advocacy Groups in the Patent System
Gilead patent for its Sovaldi hepatitis C drug is rejected in Ukraine
Global Access Expert Rohit Malpani Joins I-MAK’s Growing Team to Solve Drug Patent Problem
Ready to Leave the Private Sector for Public Service? Read This First.
Another reason to visit Egypt: Europe’s high drug prices
The Loopholes Drug Companies Use to Keep Prices High
Non-profit group continues battle against Gilead patents
Medicines access group takes aim at Sovaldi patents
As more countries around the world reject unmerited patents for Sovaldi®, I-MAK Files Two New U.S. Patent Challenges on Gilead’s Hepatitis C Portfolio